Back to News
Market Impact: 0.35
MetaVia Inc. Announces Positive Interim Data from Part 3B of Phase 1 Clinical Trial of DA-1726
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
MetaVia reported interim Phase 1 data for DA-1726 showing a 68% placebo-adjusted reduction in liver fat in Part 3B. The article text is truncated, so it does not provide additional trial details or safety findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
MTVA0.80
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO